reports
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commerc...
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial s...
DBV Technologies annonce la nomination de Kevin Trapp, dirigeant chevr...
DBV Technologies annonce la nomination de Kevin Trapp, dirigeant chevronné du secteur, au poste de Directeur Commercial Châtillon, France, le 3 novembre (22 : 30 CET) 2025 DBV Technologies annonce la nomination de Kevin Trapp, dirigeant chevronné du secteur, au poste de Directeur Commercial DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT— CUSIP : 23306J309), une société biopharmaceutique de stade clinique, a annoncé ce jour la nomination de Kevin Trapp au poste de Directeur Commercial, avec effet immédiat. Dans ses fonctions, M. Trapp rapportera direct...
Information Regarding the Total Number of Voting Rights and Total Numb...
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025 Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 10/31/2025 179,827,919 Total gross of voting rights: 179,827,919 Total net* of voting rights: 179,741,847 * Net total = tota...
Information relative au nombre total des droits de vote et d’actions c...
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 octobre 2025 Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 octobre 2025 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE Euronext Paris Code ISIN : FR 0010417345 Date Nombre total d’actions composant le capital social Nombre total de droits de vote 31/10/2025 179.827.919 Total brut des droits de vote : 179.827.919 ...
Novartis AG: 1 director
A director at Novartis AG sold 2,500 shares at 98.528CHF and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board ...
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the “Board”), effective October 30, 2025. Dr. Lee is appointed in replacement of Daniel Soland, subject to the ratification by...
DBV Technologies annonce la nomination de Philina Lee, Ph.D. au sein d...
DBV Technologies annonce la nomination de Philina Lee, Ph.D. au sein de son Conseil d’administration Châtillon, France, 30 octobre 2025 DBV Technologies annonce la nomination de Philina Lee, Ph.D. au sein de son Conseil d’administration DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (la « Société » ou « DBV »), une société biopharmaceutique au stade clinique, a annoncé ce jour la nomination provisoire d’une nouvelle administratrice indépendante, le Docteur Philina Lee, au sein de son Conseil d’administration (le « Conseil »), effective à compter du 30 octob...
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientif...
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting Châtillon, France, October 30, 2025 DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting, November 6 - 10, in Orlando, Florida. DBV will host a Product Theater titled “Harnessing Immune Plasticity to Alte...
DBV Technologies participe au congrès scientifique annuel de l'ACAAI
DBV Technologies participe au congrès scientifique annuel de l'ACAAI Châtillon, France, le 30 octobre 2025 DBV Technologies participe au congrès scientifique annuel de l'ACAAI DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT – CUSIP : 23306J309) une société biopharmaceutique en phase clinique, a annoncé sa participation au congrès scientifique annuel 2025 de l'American College of Allergy, Asthma & Immunology (ACAAI), qui se tiendra du 6 au 10 novembre à Orlando, en Floride. DBV organisera un forum produit intitulé « Harnessing Immune Plasticity to Alt...
DBV Technologies Announces Sale of approximately $30 million of ADSs T...
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq Châtillon, France, October 29, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, pursuant to the Company’s At-The-Market program established on September 5, 2025 (the “ATM Program”), it has agreed to issue and sell new ordinary shares...
DBV Technologies annonce un placement d’ADS pour un montant d’environ ...
DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq Châtillon, France, 29 octobre 2025 DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq DBV Technologies (la « Société » ou « DBV ») (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Capital Market : DBVT), société biopharmaceutique en phase clinique, annonce ce jour, dans le cadre de son programme de financement dit « At-The-M...
- Dominic Rose
- Naresh Chouhan
DBV Technologies Reports Third Quarter 2025 Financial Results
DBV Technologies Reports Third Quarter 2025 Financial Results Châtillon, France, October 28, 2025 DBV Technologies Reports Third Quarter 2025 Financial Results DBV closes Q3 2025 with a cash and cash equivalents balance of $69.8 million, taking cash runway into the third quarter of 2026 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company (the "Company"), reported financial results for the third quarter of 2025. The quarterly and nine months unaudited financial statements were approved by the Boar...
DBV Technologies publie ses résultats financiers du troisième trimestr...
DBV Technologies publie ses résultats financiers du troisième trimestre 2025 Châtillon, France, 28 octobre 2025 DBV Technologies publie ses résultats financiers du troisième trimestre 2025 DBV clôture le troisième trimestre 2025 avec un solde de trésorerie & équivalents de trésorerie de 69,8 millions de dollars permettant de financer l’activité jusqu'au troisième trimestre 2026 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), une société biopharmaceutique au stade clinique spécialisée dans les options de traitement des allergies alimen...
- Ana Arjona-Martinez
- Chaima Ferrandon
- Emmanuel Matot
- Sven Edelfelt
DG VINCI SA
GALP GALP ENERGIA SGPS SA CLASS B
BN DANONE SA
KPN ROYAL KPN NV
GFC GECINA SA
NOVN NOVARTIS AG
FGR EIFFAGE SA
RF EURAZEO SA
FRE FRESENIUS SE & CO. KGAA
CAP CAPGEMINI SE
SY1 SYMRISE AG
BC8 BECHTLE AG
PGHN PARTNERS GROUP HOLDING AG
IBE IBERDROLA SA
TKO TIKEHAU CAPITAL SCA
SIGN SIG COMBIBLOC GROUP LTD
EQT EQT AB
ANTIN ANTIN INFRASTRUCTURE PARTNERS
CVC CVC CAPITAL PARTNERS PLC
AAL ANGLO AMERICAN PLC
- Ana Arjona-Martinez
- Chaima Ferrandon
- Emmanuel Matot
- Sven Edelfelt
DG VINCI SA
GALP GALP ENERGIA SGPS SA CLASS B
BN DANONE SA
KPN ROYAL KPN NV
GFC GECINA SA
NOVN NOVARTIS AG
FGR EIFFAGE SA
RF EURAZEO SA
FRE FRESENIUS SE & CO. KGAA
CAP CAPGEMINI SE
SY1 SYMRISE AG
BC8 BECHTLE AG
PGHN PARTNERS GROUP HOLDING AG
IBE IBERDROLA SA
TKO TIKEHAU CAPITAL SCA
SIGN SIG COMBIBLOC GROUP LTD
EQT EQT AB
ANTIN ANTIN INFRASTRUCTURE PARTNERS
CVC CVC CAPITAL PARTNERS PLC
AAL ANGLO AMERICAN PLC
- Martial Descoutures
- Martial Descoutures
- Oliver Metzger
Fresenius SE & CO KGaA : Upgrade based on strong bottom line growth dr...
We have upgraded our rating to Outperform (from Neutral) with a new target price of € 59 based on strong growth dynamics at the biopharma business and more favourable momentum with improving profitability at Helios Germany. We have raised our EPS estimates by 3% to 7%. Valuation multiples appear highly attractive given the growth trend on the bottom line.
Press release: Sanofi successfully prices USD 3 billion of bond issue
Press release: Sanofi successfully prices USD 3 billion of bond issue Sanofi successfully prices USD 3 billion of bond issue Paris, France – October 28, 2025 - Sanofi announces that it has successfully priced its offering of $3 billion of notes across 5 tranches: $400 million fixed rate notes, due November 2027, bearing interest at a rate of 3.75%. $500 million floating rate notes, due November 2027, bearing interest at compounded SOFR plus 0.46%. $400 million fixed rate notes, due November 2028, bearing interest at a rate of 3.80%. $500 million floating rate notes, due November 202...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.